

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 May 2025 (22.05.2025)



(10) International Publication Number
WO 2025/106418 A1

(51) International Patent Classification:
A61K 31/57 (2006.01) *A61P 25/24* (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2024/055488

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:
12 November 2024 (12.11.2024)

(25) Filing Language: English

(26) Publication Language: English

Published:

- with international search report (Art. 21(3))

(30) Priority Data:
63/598,495 13 November 2023 (13.11.2023) US
63/561,060 04 March 2024 (04.03.2024) US
63/635,832 18 April 2024 (18.04.2024) US

(71) Applicant: **SEAPORT THERAPEUTICS, INC.**
[US/US]; 6 Tide Street, Boston, Massachusetts 02210 (US).

(72) Inventors: **CHEN, Michael C.**; 223 Winslow Avenue, Norwood, Massachusetts 02062 (US). **BONNER, Daniel Kenneth**; 22 Osprey Road, Sharon, Massachusetts 02067 (US). **SHIPLEY, James E.**; 3517 Roseau Drive, Punta Gorda, Florida 33950 (US). **SCHNEE, Janet M.**; 20 Winton Farm Road, Newtown, Connecticut 06470 (US). **ELENKO, Eric**; 1 Franklin Street, #1903, Boston, Massachusetts 02110 (US).

(74) Agent: **POWERS, Matthew J.** et al.; Womble Bond Dickinson (US) LLP, Independence Wharf, 470 Atlantic Avenue, Suite 600, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: LIPID PRODRUGS OF ALLOPREGNANOLONE AND USES THEREOF

(57) Abstract: Disclosed herein are methods of treating a subject in need thereof with an orally-administered lipid prodrug of allopregnanolone. The methods described herein may be used for the treatment of major depressive disorder (MDD) with anxious distress or major depressive disorder (MDD) without anxious distress.

WO 2025/106418 A1